TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of subjects meeting the definition of improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical characteristics of imported malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence under Fasting Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence under Fed Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroresponse of vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Neurologic and cognitive development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Ratios of Antibodies Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in microbiome stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New symptomatic fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: New or worsening morphometric fractures of the thoraco-lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLT) in Cycle 1
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of carfilzomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of spontaneous vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in alignment error cases greater than 3°
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Bicarbonate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TMJ disorder cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on cognitive task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clinical and Radiological Complete Clinical Response (crCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulation level required to elicit visual phosphene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of stimulation-induced visions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial localization of stimulation to produce visual phenomena
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Maintaining Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling frequency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean Monocular Distance-corrected Near Visual Acuity (VA) at 40 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical rating SCORE (SRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in the number and intensity of headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Liver related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Formoterol AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Apoptosis in circulating T cells and plaque T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Enrichment of rare coding genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF abeta levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Anti-Retroviral Therapy (ART) (re)-initiation or ART modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load (VL) and method of measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total active motion degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual analog scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in metacarpophalangeal joint circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estrogen receptor (ER) expression changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cancer related symptoms composite score change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endoscopic score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale-Part III (UPDRS-III) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of myocardium demonstrating late gadolinium enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extracellular Volume (ECV) Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain intensity score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Impact on clinical decision making
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Validated abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC of levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Relapse-free recurrence
Endpoint domain: Mortality/survival
Primary endpoint: plasma concentrations of L-dopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular systolic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histopathology of tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Steroid receptor status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in opioid use based on self-reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in opioid use based on toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychiatric symptoms - Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in hypoxic induced factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: innate immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Wong-Baker FACES Pain Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average hours of exercise per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average numerical rating score (NRS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of induction of remission after 28 days of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound Attenuation Parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serological indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of MRI findings with pain phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of MRI findings with chronic systemic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Sedatives Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estrogen receptor (ER) status evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants That Experience a Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Trough FEV1 at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to the Medical Therapeutic Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child health and development
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under the Curve (AUC) of Percent Change in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum concentration of soluble TWEAK
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of combined model of spleen stiffness and liver stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinic systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TB-related Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for TAK-117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ankle joint alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: fibular position in relation to the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: tibiotalar contact ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in non-HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Late toxicity greater than or equal to grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: adherence to antiretroviral medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients disclosing dietary supplement use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fold-Change From Baseline in Atopic Dermatitis Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rate, frequency, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants with Endoscopic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Participants With Clinical Remission CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in in situ food assessment score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in role-play food assessment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in child-report food assessment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of successes
Endpoint domain: Physiological/clinical
Primary endpoint: New appearing pathogenic bacteria in the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Michigan Incontinence Symptom Index (M-ISI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: increases in bone quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the O'Leary-Sant symptom score (OSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of BuMel Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Healthy Participants Negative for Reaction at 24 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Tuberculosis (TB) Participants Positive for Reaction at 24 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Faces Pain Rating Scale (FACES) from baseline to 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Faces Pain Rating Scale (FACES) from baseline to 8 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma Concentration (Cmax) of Norethindrone (NET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve over the dosing interval AUC(TAU) of Norethindrone (NET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma Concentration (Cmax) of Ethinyl Estradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve over the dosing interval AUC(TAU) of Ethinyl Estradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of donor sites healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wet Sputum Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dry Sputum Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Measured as a Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systolic peripheral blood pressure at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concordance between genomic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ctDNA dynamic monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change over time in Body Dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change over time in Thin Ideal Internalization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consumption of morphine in milligrams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expulsion rate of stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrences of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Regulation of fMRI activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in fMRI functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Placental malaria parasite density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maternal hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Diagnosis of Helicobacter Pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy at 42 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of MCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bowel obstruction resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Canadian Acute Respiratory Illness and Flu Scale (CARIFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chronic Obstructive Pulmonary Disease Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emotional enhancement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fMRI brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) Based on Vaccinia-specific Individual Peak PRNT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Serious Adverse Events Associated With IMVAMUNE® Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: obstructed defecation symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Lesion Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Survival
Endpoint domain: Mortality/survival
Primary endpoint: Successful data collection during hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful data collection during at home monitoring
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Graft safety
Endpoint domain: Adverse events/effects
Primary endpoint: Recipient safety (any adverse event)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving Pre-defined Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Pre-defined Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Guidance of chemotherapy based on MiCK assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tau levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of LDV/SOF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection and characterisation of nano particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Arterial Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality changes in day 10
Endpoint domain: Mortality/survival
Primary endpoint: Mortality changes in day 30
Endpoint domain: Mortality/survival
Primary endpoint: Changes of PaO2/FiO2 Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence Event of Sustained Ventricular Tachycardia or ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve of SARS-COV-2 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Measurement of succinate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerability of JVRS-100
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of screw outside the vertebral body
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in non-vellus hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subject assessment of hair growth and quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: final intra-operative joint balance within 2 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient reported outcome measures (PROMs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in viral load of hepatitis C virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical ultrasound performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health Disorder Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of GFAP and CD cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change from baseline IOP reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of malignant lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Airway Reactivity as Measured by Methacholine Challenge (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes